David Hosking

Summary

Affiliation: University Hospital Aintree
Country: UK

Publications

  1. ncbi request reprint Pharmacological therapy of Paget's and other metabolic bone diseases
    David Hosking
    Division of Mineral Metabolism, City Hospital, Nottingham NG5 1PB, UK
    Bone 38:S3-7. 2006
  2. ncbi request reprint Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study
    David Hosking
    Nottingham City Hospital, David Evans Medical Research Centre, Nottingham, UK
    Curr Med Res Opin 19:383-94. 2003
  3. ncbi request reprint Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate
    David Hosking
    City Hospital, Nottingham, UK
    J Bone Miner Res 22:142-8. 2007
  4. ncbi request reprint Management of osteoporosis with PTH: treatment and prescription patterns in Europe
    David Hosking
    Division of Mineral Metabolism, City Hospital, Nottingham, UK
    Curr Med Res Opin 25:263-70. 2009
  5. ncbi request reprint Hyperparathyroidism in the elderly patient
    Rebecca Sims
    Department of Nephrology, City Hospital, Nottingham, UK
    Drugs Aging 21:1013-24. 2004
  6. ncbi request reprint A comparison of calcaneal dual-energy X-ray absorptiometry and calcaneal ultrasound for predicting the diagnosis of osteoporosis from hip and spine bone densitometry
    Derek Pearson
    Nottingham City Hospital NHS Trust, University Hospital NHS Trust, Nottingham, UK
    J Clin Densitom 6:345-52. 2003
  7. ncbi request reprint Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis
    Lois E Wehren
    University of Maryland School of Medicine, Baltimore, MD, USA
    Curr Med Res Opin 20:525-31. 2004
  8. ncbi request reprint Ten years' experience with alendronate for osteoporosis in postmenopausal women
    Henry G Bone
    Michigan Bone and Mineral Clinic, Detroit 48236, USA
    N Engl J Med 350:1189-99. 2004
  9. ncbi request reprint Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international
    David M Reid
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK
    Clin Drug Investig 26:63-74. 2006
  10. ncbi request reprint Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    N Engl J Med 353:898-908. 2005

Detail Information

Publications11

  1. ncbi request reprint Pharmacological therapy of Paget's and other metabolic bone diseases
    David Hosking
    Division of Mineral Metabolism, City Hospital, Nottingham NG5 1PB, UK
    Bone 38:S3-7. 2006
    ..Intermittent IV administration of potent bisphosphonates constitutes an intriguing strategy for treatment of Paget's disease and other metabolic bone diseases...
  2. ncbi request reprint Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study
    David Hosking
    Nottingham City Hospital, David Evans Medical Research Centre, Nottingham, UK
    Curr Med Res Opin 19:383-94. 2003
    ..The study enrolled 549 postmenopausal women (ALN 219, RIS 222 and placebo (PBO) 108) who were > or =60 years of age at outpatient centres...
  3. ncbi request reprint Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate
    David Hosking
    City Hospital, Nottingham, UK
    J Bone Miner Res 22:142-8. 2007
    ..This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy...
  4. ncbi request reprint Management of osteoporosis with PTH: treatment and prescription patterns in Europe
    David Hosking
    Division of Mineral Metabolism, City Hospital, Nottingham, UK
    Curr Med Res Opin 25:263-70. 2009
    ....
  5. ncbi request reprint Hyperparathyroidism in the elderly patient
    Rebecca Sims
    Department of Nephrology, City Hospital, Nottingham, UK
    Drugs Aging 21:1013-24. 2004
    ..These considerations mean that it is not possible to consider the merits of pharmacological therapy for primary hyperparathyroidism without reviewing the relative merits of minimally invasive and conventional surgery...
  6. ncbi request reprint A comparison of calcaneal dual-energy X-ray absorptiometry and calcaneal ultrasound for predicting the diagnosis of osteoporosis from hip and spine bone densitometry
    Derek Pearson
    Nottingham City Hospital NHS Trust, University Hospital NHS Trust, Nottingham, UK
    J Clin Densitom 6:345-52. 2003
    ..7 and for QUS was -2.4. These results are similar to the manufacturer's recommendations. There is no significant difference in performance between the PIXI and QUS...
  7. ncbi request reprint Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis
    Lois E Wehren
    University of Maryland School of Medicine, Baltimore, MD, USA
    Curr Med Res Opin 20:525-31. 2004
    ..To compare the effectiveness of antiresorptive agents in reducing the risk of vertebral and non-vertebral fractures using data from published meta-analyses and the technique of adjusted indirect comparisons...
  8. ncbi request reprint Ten years' experience with alendronate for osteoporosis in postmenopausal women
    Henry G Bone
    Michigan Bone and Mineral Clinic, Detroit 48236, USA
    N Engl J Med 350:1189-99. 2004
    ..Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years...
  9. ncbi request reprint Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international
    David M Reid
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK
    Clin Drug Investig 26:63-74. 2006
    ....
  10. ncbi request reprint Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    N Engl J Med 353:898-908. 2005
    ..Zoledronic acid, a bisphosphonate administered as a single intravenous infusion, might meet these needs...
  11. ncbi request reprint Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis
    Alan C Perkins
    University Hospital, Medical School, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Int J Pharm 311:20-5. 2006
    ....